

APPLICATION  
FOR  
UNITED STATES OF AMERICA

\*\*\*\*\*

SPECIFICATION

TO ALL WHOM IT MAY CONCERN:

Be it known that I,

Daniele GALAVOTTI  
Italian citizen  
of MIRANDOLA - ITALY

have invented certain improvements in

“BIOREACTOR, PARTICULARLY FOR BIOARTIFICIAL ORGANS”

of which the following description in connection with the accompanying drawings is a specification, like reference characters on the drawings indicating like parts in the several figures.

The present invention relates to a bioreactor, particularly for bioartificial organs.

### BACKGROUND OF THE INVENTION

5 Bioreactors used in the biological, microbiological and medical field, for example for the perfusion of cultures of animal or human cells or for the creation of bioartificial organs, where the expression "bioartificial organ" is used to designate extracorporeal devices capable of supporting or temporarily compensating for insufficient functions of organs of a human  
10 being, have long been known.

Bioreactors used to create bioartificial organs can host cultures of animal or human cells capable of reproducing the specific functions of the organ to be supported.

Merely by way of example, bioreactors are used to create bioartificial  
15 livers, which are extracorporeal devices substantially constituted by a filtration unit, which separates the fluid to be processed, plasma or ultrafiltrate, from the corpuscular components of blood drawn from a patient; by a bioreactor, which contains a culture of metabolically active hepatocytes and is crossed by the fluid to be processed; and by a unit for  
20 recombining the processed fluid in output from the bioreactor with the corpuscular components of the blood, which is then reinjected into the patient.

The bioreactor must allow contact between the fluid to be processed and the hepatocytes, so that an exchange suitable to rebalance the  
25 concentration of the components of the fluid and of the gases dissolved therein occurs, and so that at the same time the passage of hepatocytes or of fragments thereof in said fluid is prevented, in order to avoid patient immunization phenomena.

The first bioreactors used specifically for bioartificial livers were  
30 built by using dialysis machines as their model and by using the basic

principles of dialysis processes.

There has been a transition from the early flat-membrane bioreactors to the more recent bioreactors with bundles of hollow capillary fibers, on the outside or inside of which the cell cultures are accommodated.

5       The use of hollow capillary fibers has allowed to improve diffusion and exchange processes between the fluid to be processed and the cell cultures and to provide the oxygen input required for the metabolism of these cultures.

10       However, these known bioreactors have had some drawbacks, including the fact that the exchange between the cell culture that they host and the fluid to be processed that passes through them occurs unevenly, inconstantly and partially on the useful exchange surface, with a consequent limited utilization of their actual exchange capacity and a reduction of their efficiency.

15       This is due both to the low pressure at which it is necessary to introduce the fluid to be processed, in order to avoid subjecting the cells of the culture to stresses that would compromise their vitality, and to the shape and configuration of the supporting structure of the cell cultures, which cause a concentration of the exchange at the region where the fluid enters  
20       the bioreactor instead of distributing it over the entire useful surface.

Another drawback of known bioreactors is that the useful volume for the cell culture is greatly reduced with respect to their total volume, the former being on the order of one third of the latter; this, combined with the need to have a sufficient cell concentration capable of replacing the  
25       functions of the organ to be supported, entails an increase in the overall dimensions of bioreactors.

In order to obviate these drawbacks, bioreactors with hollow capillary fibers are known which are essentially constituted by a substantially tubular container which internally accommodates a cell culture and support  
30       structure and is provided, at one end, with a port for the inflow of the fluid

to be processed, which is arranged upstream of the structure, and at the opposite end with a port for the outflow of the processed fluid, which is arranged downstream of the structure.

Upstream of the support and culture structure there is a first chamber  
5 for collecting the fluid to be processed, which is connected to the outside of the container by means of the inflow port; downstream of the support and culture structure there is a second chamber for collecting the processed fluid, which is connected to the outside of the container by means of the outflow port.

10 The support and culture structure is constituted by a multilayer panel, which is wound in a spiral around a coupling stem that is substantially coaxial to the container, is internally hollow and has a blind end and another open end that is connected to the outside of said container.

The panel has an edge that is rigidly coupled, by interlocking and/or  
15 gluing, to a longitudinal slit formed in the stem, and the opposite edge that is in contact with the inside wall of the container; the opposite ends of the spiral are embedded in a respective containment ring.

The panel is constituted by at least six superimposed flat layers: a first layer, constituted by an order of capillary hollow fibers for the outflow of  
20 the processed fluid, which are parallel to the axis of the container and are bent in a U-shape so that their free ends lead into the second collection chamber; a second layer, which is constituted by a permeable and filtering cell support medium; a third layer, which is constituted by a lattice for distribution of the cells to be seeded; a fourth layer, which is identical to the  
25 second layer; a fifth layer, which is constituted by an order of capillary hollow fibers for the inflow of the fluid to be processed, which are parallel to the axis of the container and are bent in a U-shape in the opposite direction with respect to the fibers of the first layer, so that their free ends lead into the first collection chamber; and finally, a sixth layer, which is  
30 constituted by an impermeable sheet that separates the capillary fibers of the

first and fifth layer when the panel is wound in a spiral.

The cells to be seeded in the culture and support structure are inoculated, through the open end of the stem, into the cavity of said stem; the inoculated cells diffuse throughout the structure through the edge of the panel that is fixed to the stem.

Once seeding of the cells has ended, the bioreactor can be used as a bioartificial organ: the fluid to be processed is introduced through the inflow port into the first collection chamber and from there penetrates into the inflow fibers; after saturating them, it passes through their walls, and by following a substantially radial flow it reaches the layer that supports the cells with which the exchange of solutes occurs.

The fluid thus processed, again following a flow that is substantially radial with respect to the axis of the container, reaches the outflow fibers, and penetrates inside them through their walls in order to flow out into the second collection chamber and be evacuated through the outflow port.

These last known bioreactors, while having allowed to overcome the drawbacks noted earlier by allowing to provide a uniform exchange over the entire useful surface and to better utilize the available volume, nonetheless have drawbacks, including the fact that they have a very complex structure, require long, laborious and accurate assembly operations, and require the use of various kinds of material, with a consequent increase in production costs and times.

It is noted, for example, that precise operations for interlocking and bonding the edge of the panel to the central stem with adhesive are required.

Moreover, it is noted that the multilayer panel has a very complex configuration, which requires the superimposition of a plurality of different layers, including an impermeable one that is suitable to separate the hollow inflow fibers from the outflow fibers, so as to avoid any mixing of the fluid to be processed and the already-processed fluid.

### SUMMARY OF THE INVENTION

The aim of the present invention is to eliminate the above-mentioned drawbacks of known bioreactors, by providing a bioreactor, particularly for bioartificial organs, that is structurally and constructively simpler, allows to  
5 limit and facilitate assembly operations, and allows to reduce the use of different types of material and to contain production times and costs.

Within this aim, an object of the present invention is to provide a bioreactor that has a simple structure, is relatively easy to provide in practice, safe in use, effective in operation, and has a relatively low cost.

10 This aim and these and other objects that will become better apparent hereinafter are achieved by the present bioreactor, particularly for bioartificial organs, which comprises a closed and substantially tubular body inside which there is a containment cavity; an animal and/or human cell culture and support structure, accommodated in said cavity and suitable to  
15 be crossed by a fluid to be processed; a port for the inflow of said fluid to be processed, which is formed in said body upstream of said structure; a port for the outflow of the processed fluid, which is formed in said body downstream of said structure; a first chamber for collecting the fluid to be processed, which is formed in said cavity upstream of said structure and is  
20 connected to the outside of said body by means of said inflow port; and a second chamber for collecting the processed fluid, which is formed in said cavity downstream of said structure and is connected to the outside of said body by means of said outflow port; characterized in that it comprises a first bundle of hollow capillary fibers for the inflow of said fluid to be processed,  
25 which is accommodated in said cavity and interposed between said first collection chamber and said structure, and a second bundle of hollow capillary fibers for the outflow of said processed fluid, which is accommodated in said cavity and is interposed between said structure and said second collection chamber.

### BRIEF DESCRIPTION OF THE DRAWINGS

Further characteristics and advantages of the present invention will become better apparent from the following detailed description of a preferred but not exclusive embodiment of a bioreactor, particularly for  
5 bioartificial organs, illustrated by way of non-limiting example in the accompanying drawings, wherein:

Figure 1 is a schematic sectional view, taken along a longitudinal plane, of a bioreactor, particularly for bioartificial organs, according to the invention;

10 Figure 2 is an enlarged-scale schematic sectional view, taken along a transverse plane, of a portion of the cell support and culture structure of the bioreactor according to the invention;

Figure 3 is a schematic axonometric view of a portion of the cell support and culture structure and of the first and second bundles of fibers of  
15 the bioreactor according to the invention;

Figure 4 is a schematic plan view of the first and second bundles of fibers of an alternative embodiment of the bioreactor according to the invention.

### DESCRIPTION OF THE PREFERRED EMBODIMENTS

20 With reference to the figures, the reference numeral 1 generally designates a bioreactor, particularly for bioartificial organs.

The bioreactor 1 comprises a substantially tubular closed body 2, inside which there is a containment cavity 3, and an animal and/or human cell culture and support structure 4, which is accommodated in the cavity 3  
25 and is suitable to be crossed by a fluid to be processed, such as for example plasma or ultrafiltrate.

The body 2 is provided with a port 5 for the inflow of the fluid to be processed, which is formed upstream of the structure 4, and with a port 6 for the outflow of the processed fluid, which is formed downstream of the  
30 structure 4.

Inside the cavity 3 and upstream of the structure 4 there is a first chamber 7 for collecting the fluid to be processed, which is connected to the outside of the body 2 by means of the inflow port 5; also inside the cavity 3, but downstream of the structure 4, there is a second chamber 8 for collecting  
 5 the processed fluid, which is connected to the outside of the body 2 by means of the outflow port 6.

The bioreactor 1 further comprises a first bundle 9 of hollow capillary fibers 10 for the inflow of the fluid to be processed, which is accommodated in the cavity 3 and is interposed between the first chamber 7 and the  
 10 structure 4, and a second bundle 11 of hollow capillary fibers 12 for the outflow of the processed fluid, which is accommodated in the cavity 3 and is interposed between the structure 4 and the second chamber 8.

First anchoring means 13 and second anchoring means 14 respectively fix the first bundle 9 and the second bundle 11 with respect to  
 15 the body 2.

The body 2 comprises two opposite ends 2a and 2b, respectively upstream and downstream of the structure 4, which are closed hermetically by respective covers 15 and 16 with corresponding interposed gaskets 17 and 18.

20 The inflow port 5 is formed in the cover 15 and the outflow port 6 is formed in the cover 16; the two ports are substantially coaxial to the longitudinal axis of the body 2, the corresponding outline of which has been designated by the reference letter A.

The first chamber 7 remains defined between the cover 15 and the  
 25 first anchoring means 13; the second chamber 8 is formed between the cover 16 and the second anchoring means 14.

Moreover, the bioreactor 1 is provided with an inlet 19 for inoculating the cells that will be cultured and supported by the structure 4 and with an outlet 20 for evacuating the inoculated cells that have not  
 30 adhered to the structure 4; the inoculation inlet 19 and the evacuation outlet



20 are formed in the body 2 between the first bundle 9 and the second bundle 11.

In particular, the inoculation inlet 19 is formed between the second bundle 11 and the structure 4, while the evacuation outlet 20 is formed  
5 between the structure 4 and the first bundle 9.

A chamber 21 for the inflow of the inoculated cells is formed in the cavity 3, between the second bundle 11 and the structure 4, and is connected to the outside of the body 2 by means of the inoculation inlet 19.

A chamber 22 for the outflow of the inoculated cells that have not  
10 adhered to the structure 4 is formed in the cavity 3 between the structure 4 and the first bundle 9 and is connected to the outside of the body 2 by means of the evacuation outlet 20.

Plugs for closing the inoculation inlet 19 and the evacuation outlet 20 are provided and are not shown since they are of a known type.

15 The structure 4 comprises a panel 23 that is wound up in a roll or spiral so that its axis is substantially parallel to the axis A of the body 2; the longitudinal edge of the panel 23 inside the roll is free and its opposite longitudinal end is also free and in contact with the inside wall of the cavity 3.

20 The panel 23 is wound around said inner longitudinal edge through an arc of at least 270°.

The panel 23 comprises at least two mutually superimposed and parallel plate-like layers: a first layer 24, which is constituted by a cell support matrix, and a second layer 25, which is constituted by an inoculated  
25 cell diffusion and distribution matrix.

Advantageously, the panel 23, in an embodiment that is not shown, can comprise a third layer that is identical to the first layer 24 and is superimposed and parallel with respect to the second layer 25.

The first layer 24 is of a type that is permeable with respect to the  
30 fluid to be processed and can be constituted by sheets of polymeric fabric

with a crossed weave having a random or ordered arrangement, such as for example polyester or the like.

The total volume of the first layer 24 and/or of the optional third layer is comprised between 5 and 15% of the total volume available for the cells.

5       The second layer 25 instead has a lattice-like structure and is made for example of polyester.

      The first bundle 9 comprises one or more flat superimposed orders of hollow capillary fibers 10, which are arranged substantially parallel to the axis A of the body 2 and are individually bent in a U-shape, so that their  
10       respective open ends are directed toward the first chamber 7, such fibers 10 being permeable to the fluid to be processed. The second bundle 11 comprises one or more flat superimposed orders of hollow capillary fibers 12, which are arranged substantially parallel to the axis A of the body 2 and are individually folded in a U-shape, with their respective open ends  
15       directed toward the second chamber 8, the fibers 12 being permeable to the processed fluid.

      Each fiber 10 and 12, respectively of the first bundle 9 and of the second bundle 11, is constituted by a segment of a capillary tube made of microporous material, which is bent in a U-shape substantially at the  
20       centerline so as to form two straight branches 10a and 12a that are mutually substantially parallel, with open ends that lead respectively into the first chamber 7 and into the second chamber 8.

      The microporous material of which the fibers 10 and 12 are constituted has pores whose average diameter is comprised between 0.10  
25       μm and 0.50 μm and is constituted for example by polyether sulfone or the like.

      Conveniently, the distribution density and the diameter of the fibers 10 and 12 are constant along the entire extension of the first bundle 9 and of the second bundle 11 respectively.

30       The first anchoring means 13 and the second anchoring means 14

comprise a respective shim 26 and 27 made of a sealing material, which is accommodated snugly in the cavity 3, is arranged substantially at right angles to the axis A of the body 2, and in which the branches 10a and 12a of the fibers 10 and 12 of the first bundle 9 and of the second bundle 11 respectively are embedded at least partially.

The material of which the shims 26 and 27 are made is of the polymeric type, for example based on polyurethane or the like.

Figure 4 is a view of a portion of an alternative embodiment of the bioreactor 1, in which the first bundle 9 of fibers 10 comprises at least two flat and superimposed orders of hollow capillary fibers 10' and 10'', which are permeable to the fluid and are individually bent in a U-shape, so that their respective open ends are directed toward the first chamber 7; the fibers 10' of one of the two orders are arranged, with respect to the fibers 10'' of the other order, at an angle  $\alpha$  that is variable between  $15^\circ$  and  $30^\circ$ .

Likewise, the second bundle 11 of fibers 12 comprises at least two flat and superimposed orders of hollow capillary fibers 12' and 12'', which are permeable to the fluid and are individually bent in a U-shape, so that their respective open ends are directed toward the second chamber 8; the fibers 12' of one of the two orders are arranged, with respect to the fibers 12'' of the other order, at an angle  $\beta$  that is variable between  $15^\circ$  and  $30^\circ$ .

The bioreactor 1 can be used for example as a bioartificial liver; in this case, the cells that are supported and cultured on the structure 4 are hepatocytes, while the fluid processed therein is constituted by plasma or ultrafiltrate separated from the corpuscular components of the blood drawn from a patient.

The operation of the invention is as follows.

Before the bioreactor 1 can be used as a bioartificial organ, it is necessary to seed the structure 4 with the appropriate cells (hepatocytes).

The cells are injected through the inoculation inlet 19 into the inflow chamber 21, from which they flow toward the structure 4; the inoculated

cells diffuse through the second layer 25 into the first layer 24 of the panel 23, to which they adhere.

The cells that do not adhere to the first layer 24 flow away toward the outflow chamber 22, from which they are removed through the evacuation outlet 20 in order to be optionally returned to circulation.

The direction of the flow of the cells inside the body 2, indicated schematically by the arrows C, has a component of diffusion from the second layer 25 to the first layer 24 that is substantially perpendicular to the axis A and a component of outflow from the inoculation inlet 19 to the evacuation outlet 20 that is substantially parallel to the axis A of the body 2.

Once the seeding of the cells has ended, the inoculation inlet 19 and the evacuation outlet 20 are closed with their respective plugs; the bioreactor 1 is thus ready to be used as a bioartificial organ.

The fluid to be processed, for example the plasma or ultrafiltrate separated from the corpuscular components of the blood drawn from a patient, is pumped through the inflow port 5 into the first chamber 7, where the open ends of the fibers 10 of the first bundle 9 lead; the pumping pressure is very low, so as to avoid compromising the integrity and therefore the vitality of the cells seeded in the structure 4.

The fluid to be processed enters the open ends of the fibers 10 and penetrates their internal opening; once it has saturated said opening, it passes the pores of the walls of the fibers 10 in order to reach the outflow chamber 22 and flow from there toward the structure 4 in a direction that is substantially parallel to the axis A of the body 2.

The fluid flows through the structure 4, always following a direction that is substantially parallel to the axis A of the body 2; inside the structure 4, it makes contact with the cells seeded therein, which perform the detoxification functions assigned to them.

The fluid thus processed pours into the inflow chamber 21, while the cells are retained inside the structure 4.

The processed fluid contained in the inflow chamber 21 passes through the pores of the walls of the fibers 12 of the second bundle 11 in order to enter their internal opening; after saturating said opening, it pours into the second chamber 8, from which it flows out, through the outflow  
5 port 6, in order to be recirculated or recombined with the corpuscular components of the blood of the patient and be reinjected into said patient.

The direction of the stream of fluid that reaches the outflow port 6 from the inflow port 5 through the structure 4 is substantially parallel to the longitudinal axis A of the body 2; the fluid crosses in succession the first  
10 chamber 7, the first bundle 9 of fibers 10, the outflow chamber 22, the structure 4, the inflow chamber 21, the second bundle 11 of fibers 12, and the second chamber 8.

The flow of the fluid is shown schematically by the arrows F; it is noted that since the bioreactor is mirror-symmetrical, the direction of the  
15 flow of the fluid may also be the opposite of the one taken as reference in the present description.

In practice it has been found that the described invention achieves the intended aim and objects.

The bioreactor according to the invention is in fact structurally and  
20 constructively simpler than known bioreactors, requires a smaller number of assembly operations, and allows to limit the use of different materials.

It is noted in fact that the bioreactor according to the invention does not have the central stem for coupling the cell culture and support structure and therefore does not require the corresponding operations for interlocking  
25 and adhesive-bonding the latter to the former.

The panel of the cell culture and support structure of the bioreactor according to the invention is constituted by the superimposition of two or three layers, instead of six, and does not require an impermeable layer to separate the processed fluid from the fluid yet to be processed.

30 The bioreactor according to the invention, for an equal volume, is

longer (even by 200%) than known bioreactors but has a diameter that is reduced by as much as 50%, allowing to use standard commercially available containment bodies.

Finally, the bioreactor according to the invention allows, thanks to the  
5 longitudinal flow of the cells to be seeded and of the fluid to be processed, to optimize both in situ seeding of the cells and contact between the fluid and said cells.

The invention thus conceived is susceptible of numerous modifications and variations, all of which are within the scope of the  
10 appended claims.

All the details may further be replaced with other technically equivalent elements.

In practice, the materials used, as well as the shapes and dimensions, may be any according to requirements and to the state of the art without  
15 thereby abandoning the scope of the protection of the appended claims.

The disclosures in Italian Patent Application No. MO2003A000081, from which this application claims priority, are incorporated herein by reference.